EN DE
Watch Luxempart for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Luxempart (LXMPR) fair value: what the stock is really worth

As of Oct 23, 2026: fair value (intrinsic value) of Luxempart stock €121, price €70.00, upside +72.5%, quality 77 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Financial Services · LU

L Luxempart logo Broad data Oct 27, 2026

Luxempart

LXMPR · LU

Strongly undervaluedStrong Fair Value upside with high Quality.

The stock costs 42% less than our calculation considers fair.

Fair value €120.73 · Strongly undervalued (42%)
Quality 77/100
Highly profitable · 93.8% net margin (TTM)
Generates free cash flow
Ranks above peers (10/13)
Wide moat 77/100
Broad data
Mixed Growth (revenue 3y +60.5 %/yr in EUR)
3.7% dividend yield · Watch coverage
Watch Luxempart for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€79.50 €59.50 Fair Value €120.73 Aug 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 27, 2026.

How to read this chart

60‑month range €59.50 – €79.50 · fair‑value band €105.63 – €157.14 · the €70.00 price screens below the €120.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 27, 2026.

Follow Luxempart in your weekly email

Every Wednesday you see whether Luxempart is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Luxempart is an investment firm specializing in direct and fund of fund investments. The firm also makes secondary direct investments.

Show moreShow less

Within direct investments, it specializes in PIPE and private equity investments in middle market, later stage, mature, emerging growth, late venture, mezzanine, buyouts, acquisitions and private investment in public equity, and growth capital for small and medium sized companies.

Within Investment Funds, it specializes in venture capital, growth capital, secondary and buyouts funds. The firm seeks to invest in listed and non-listed companies.

For direct investments, the firm does not target a specific sector, but prefers to invest in companies operating in energy, media, banks, and financial services & insurance, holding companies, credit agencies, insurance brokers, healthcare, retail, industrials, security, and telecommunications sectors.

It seeks to invest in companies based in Europe including Grand Duchy of Luxembourg and nearby regions, Belux, France, Germany, Northern Italy, Belgium, Austria, and Switzerland for direct investments, and in Europe, USA and Europe for fund investments.

For direct investments it typically invests between "25 million ($27.15 million) and "100 million ($108.61 million) in companies with a minimum EBITDA of "1 million ($1.31 million), target enterprise value between "10 million ($13.11 million) and "2000 million ($2622.02 million), and with a minimum target sales value of "15 million ($19.66 million).

For Investment Funds, it usually invests between EUR 10 million ($10.85 million) and EUR 25 million (27.14 million) per fund. It aims to aid its portfolio companies to their IPO through financial aid. The firm seeks Board seats in its portfolio companies.

It prefers to take majority stakes in companies but also takes active minority stakes. Luxempart was founded in 1988, and is based in Leudelange, Luxembourg with additional offices in Belgium; Munich, Germany; Paris, France and Italy.

Stock analysis

Luxempart (LXMPR) currently trades at €70.00, while our model-based Fair Value estimate is €120.73, implying the stock looks roughly 42.0% undervalued today.

Show more

Valuation

Bull case: the Earnings-Based group reads highest at a median of €452.64 per share, and 8 of the 12 models we run sit above the €70.00 price.

Bear case: the Dividend Discount group reads lowest at €34.64, and 4 of the 12 models stay below the price. Data coverage for this calculation is high.

Scenario range: €105.63 (bear) to €157.14 (bull), the price of €70.00 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 77/100 (high quality), in the Financial Services sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Luxempart reported revenue of €276M in FY2025 versus €66.7M in FY2022, a compound +60.5%/yr. Reported net income was €261M in FY2025, compounding +77.8%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.

Key figures

Market cap €1.4B Small · P/E ratio 5.1 · P/S ratio 4.73 · EPS (TTM) €13.78 · Dividend yield 3.7% · Net margin 93.8% · Return on equity 11.5% · Return on assets 7.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (medium confidence).

What moves the price

The share trades about 10% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Financial Services peers we cover trades at −12% fair-value upside, at 72%, LXMPR screens cheaper than that median.

Fair Value models

Bear €105.63 Fair Value €120.73 Bull €157.14
Price €70.00 · Upside +72.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (€9.22 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income €108.60 €120.73 €157.14 71
Growth DCF €35.36 €63.88 €109.68 68
P/E Multiple €126.09 €168.12 €210.15 63
All 12 models by family
DCF Models
5Y P/E Exit €105.63 €254.50 €461.17 60
10Y P/E Exit €86.30 €222.57 €455.09 52
Earnings-Based
Graham-Dodd €87.94 €613.29 €860.66 59
Lynch FV €316.85 €452.64 €588.43 57
Dividend Discount
Gordon GGM €20.20 €39.85 €59.74 62
DDM Multi-Stage €20.20 €34.64 €42.12 62
Multiples
P/E Multiple €126.09 €168.12 €210.15 63
P/B Multiple €131.45 €175.27 €219.09 55
Asset-Based
NCAV (Graham) €62.60 €83.88 €125.19 51
Growth DCF
Growth DCF €35.36 €63.88 €109.68 68
Rev-Margin DCF €30.63 €51.30 €94.62 62
Economic Profit
Residual Income €108.60 €120.73 €157.14 71

Open the full fair value analysis →

Quality Score breakdown

Overall quality 77/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 53
How much profit the company makes from its sales and capital
Quality Growth 98
Are margins and returns getting better?
Cashflow 57
Do the profits arrive as real cash?
Financial strength 69
Debt, balance sheet and risk of trouble
Investment 84
Does it invest with discipline instead of growing at any price?
Low Volatility 94
How calm the share price moves, does not count
Momentum 44
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 51
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 72/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year (last 3 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+49.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+45.6%
Dividend (yield on the price)3.7%
2025 sits 462% above its own trend. The rate follows the median trend of the last 3 years, not that single year.

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+17.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +15.0% a year for the price.

Watch LXMPR, get fair value alerts →

Compare Luxempart with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Asset Management · 669 stocks

Beats the industry median on 10/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 77 · Top 25%
Fair Value upside +72.5% · Above median
Profitability
Return on equity (12 months) 11.5% · Above median
Return on assets 10.3% · Top 25%
Net margin (12 months) 93.8% · Top 25%
Operating margin (12 months) 91.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 28.7% · Above median
Dividend yield (12 months) 3.7% · Below median

Valuation Multiplesvs Asset Management median · lower = cheaper

P/E (12 months) 5.1× · Cheapest 25%
P/B 0.56× · Cheapest 25%
P/S (12 months) 4.73× · Pricier than median
Price / free cash flow 32.5× · Priciest 25%
EV/EBITDA 4.8× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 60
FUTURE (revenue growth)100 · sector 39
PAST (return on equity)46 · sector 24
HEALTH (low debt)0 · sector 95
DIVIDEND (yield)73 · sector 81

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Asset Management stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Raymond James Financial, Inc RJF $157.70 $315.40 +100% vs LXMPR
Exor N.V EXO €67.60 €135.20 +100% vs LXMPR
Apollo Global Management, Inc APO $112.83 $196.06 +74% vs LXMPR
Ameriprise Financial, Inc AMP $492.19 $590.44 +20% vs LXMPR
Ares Management Corporation ARES $117.01 $103.04 −12% vs LXMPR
State Street Corporation STT $167.83 $139.37 −17% vs LXMPR
Northern Trust Corporation NTRS $166.91 $123.42 −26% vs LXMPR
Blackstone Inc BX $118.75 $52.29 −56% vs LXMPR
Brookfield Corporation BN $37.51 $13.42 −64% vs LXMPR
KKR & Co KKR $91.34 $29.26 −68% vs LXMPR

Explore undervalued stocks

More undervalued Financial Services stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Luxempart · Fair Value
€120.73 +42%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Luxempart Fair Value". https://www.fairvalue-calculator.com/stock/LXMPR

Frequently asked questions

Is Luxempart (LXMPR) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of €120.73 versus a price of €70.00, about +72% upside (undervalued).
What is the fair value of LXMPR?
Our model-based fair value for Luxempart is €120.73 (as of Oct 27, 2026), built from audited fundamentals. The current price: €70.00.
What is the quality score of LXMPR?
Luxempart has a Quality Score of 77/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Luxempart (LXMPR)?
Our model-based price target is the fair value of €120.73 (as of Oct 27, 2026) from 12 valuation models. Cautious scenario €105.63, optimistic scenario €157.14. It is a calculation from audited fundamentals, not an analyst target.
What is the Luxempart stock forecast for 2026?
Our models put fair value at €120.73, about +72% upside versus a price of €70.00 (undervalued). Cautious scenario €105.63, optimistic scenario €157.14. The calculation is refreshed regularly with new filings.
What is the revenue of Luxempart (LXMPR)?
Luxempart reported trailing-twelve-month revenue of about €299M (latest available figure, as of Oct 27, 2026).
Does Luxempart pay a dividend?
Luxempart currently shows a dividend yield of 3.66% relative to its recent price (as of Oct 27, 2026).
What growth is priced into Luxempart (LXMPR)?
For today's price to be fair in a discounted-cash-flow model, Luxempart would have to grow free cash flow by +17.5 % per year for five years (discount rate 9.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 3 years revenue grew +60.5 % per year. As of Oct 27, 2026.
What discount rate (WACC) does the fair value of LXMPR use?
Our models discount Luxempart at 9.6 %: a base by market capitalisation (small), damped by beta 0.04, country premium for Germany. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Luxempart that is +17.5 % per year a year over ten years, using the same discount rate (9.6 %) and the same formula as our fair value.
How much growth has Luxempart (LXMPR) delivered so far?
Over the past 3 years revenue at Luxempart grew +60.5 % a year. The price currently implies +17.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Luxempart (LXMPR) growing?
The median revenue growth in the sector is +6.9 % a year. That is the yardstick for the growth priced into Luxempart (+17.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Luxempart (LXMPR)?
The free-cash-flow yield on the price is 3.08 %: that much free cash flow Luxempart produces per unit of market value. When it exceeds the discount rate of our models (9.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Luxempart (LXMPR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Luxempart it is €120.73 per share (as of Oct 27, 2026), against a price of €70.00. It is the blended result of 12 valuation models (cash flow, earnings, asset, dividend).
Is Luxempart stock overvalued or undervalued in 2026?
As of Oct 27, 2026, LXMPR trades below its calculated fair value: price €70.00, fair value €120.73, a gap of about +72% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LXMPR?
No. The price is what the market pays today (€70.00); the fair value is what the company's own numbers justify (€120.73). For Luxempart the two are €50.73 per share apart. That gap is exactly why we show both numbers side by side.
How much is Luxempart worth?
The market values Luxempart at about €1.4B (market capitalisation, as of Oct 27, 2026). Per share that is €70.00; our models calculate a fair value of €120.73 per share.
What do the bullish and bearish scenarios say about LXMPR?
Our models span a range for Luxempart: cautious scenario €105.63, base €120.73, optimistic €157.14 per share (as of Oct 27, 2026, price €70.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of LXMPR?
Luxempart trades at a price-to-earnings ratio of 5.1 (as of Oct 27, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €120.73 is built from several models across several years. Other multiples: P/B 0.6, P/S 4.7, EV/EBITDA 4.8.
How solid is the balance sheet of Luxempart (LXMPR)?
Balance-sheet figures for Luxempart (as of Oct 27, 2026): return on equity 11.5%. They feed the Quality Score of 77/100, which measures business quality independently of the share price.
How far is LXMPR from its 52-week high?
Luxempart trades at €70.00, about 10% below its 52-week high of €78.00 and 18% above the low of €59.50 (as of Oct 23, 2026). Distance from the high says nothing about value: that is what the fair value of €120.73 is for.
Which stocks are comparable to Luxempart?
From the same area (Financial Services) we also value Blackstone Inc, Brookfield Corporation, KKR & Co, Apollo Global Management, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Luxempart stock attractive at the current price?
The data as of Oct 27, 2026: price €70.00, calculated fair value €120.73 (+72%), Quality Score 77/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LXMPR calculated?
We run Luxempart through 12 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of €120.73, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.7 % above its aggregate fair value. Luxempart currently trades 42 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Luxempart (LXMPR)?
The closing price on Oct 23, 2026 was €70.00. Our model-based fair value is €120.73, about +72% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Luxempart right now?
The rarer combination: high quality (77/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (€105.63). The market is more pessimistic than our downside scenario. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.

Key figures of Luxempart

How large is the market capitalisation of Luxempart (LXMPR)?
The market capitalisation of Luxempart is €1.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Luxempart (LXMPR)?
The price-to-sales ratio of Luxempart is 4.73 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Luxempart (LXMPR)?
Earnings per share at Luxempart are €13.78 (price ÷ EPS = P/E 5.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Luxempart (LXMPR)?
The dividend yield of Luxempart is 3.7% (payout 18.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Luxempart (LXMPR)?
The net margin of Luxempart is 93.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Luxempart (LXMPR)?
The return on equity (ROE) of Luxempart is 11.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the return on assets of Luxempart (LXMPR)?
The return on assets (ROA) of Luxempart is 7.2% (last twelve months). Profit relative to everything the company owns. Harder to inflate than return on equity because debt does not boost it.
What is the operating margin of Luxempart (LXMPR)?
The operating margin of Luxempart is 91.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Luxempart (LXMPR)?
Revenue at Luxempart is growing +28.7% versus a year earlier (3y avg +60.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Luxempart (LXMPR)?
Earnings per share at Luxempart are growing +31.9% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed

Watch Luxempart in the live analysis

One click puts Luxempart on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.